Argenica Therapeutics (ASX:AGN) posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug (IND) application to be submitted by the end of 2024, according to a Wednesday research note from Euroz Hartleys.
The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.
AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.
In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.
Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。